1. Home
  2. SOC vs CADL Comparison

SOC vs CADL Comparison

Compare SOC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sable Offshore Corp.

SOC

Sable Offshore Corp.

N/A

Current Price

$1.91

Market Cap

713.8M

Sector

N/A

ML Signal

N/A

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

N/A

Current Price

$8.70

Market Cap

641.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOC
CADL
Founded
2020
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.8M
641.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SOC
CADL
Price
$1.91
$8.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
10
Target Price
$9.80
★ $22.11
AVG Volume (30 Days)
★ 7.2M
1.0M
Earning Date
11-09-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
54.61
★ 58.62
EPS
N/A
★ N/A
Revenue
N/A
★ $125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$77.35
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$4.35
52 Week High
$19.25
$14.00

Technical Indicators

Market Signals
Indicator
SOC
CADL
Relative Strength Index (RSI) 19.31 46.63
Support Level N/A $7.70
Resistance Level $5.38 $9.42
Average True Range (ATR) 0.23 0.61
MACD -0.10 0.13
Stochastic Oscillator 7.64 62.27

Price Performance

Historical Comparison
SOC
CADL

About SOC Sable Offshore Corp.

Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: